SCHEMBL2853407

SCHEMBL2853407

CCN(CCNS(=O)(=O)c1cccc(C(N)=O)c1)c1cccc(C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.52
▸ GFER P55789 3/20 0.52
▸ MAPT P10636 3/20 0.52
▸ HPGD P15428 2/20 0.52
▸ HTT P42858 2/20 0.52
▸ KDM4E B2RXH2 1/20 0.52
▸ GAA P10253 1/20 0.52
▸ AKR1C3 P42330 3/20 0.50
▸ TSHR P16473 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ KMT2A Q03164 2/20 0.49
▸ LMNA P02545 2/20 0.45
▸ CYP2C19 P33261 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ PARP1 P09874 1/20 0.44
▸ TP53 P04637 2/20 0.43
▸ GUSB P08236 1/20 0.43
▸ RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2853408 0.84 KMT2A (0.53) ALDH1A1GFERMAPTHPGDHTT
SCHEMBL2848724 0.82 ALDH1A1 (0.60) ALDH1A1GFERKDM4EAKR1C3SMN1; SMN2
SCHEMBL2850679 0.79 CYP2C19 (0.53) ALDH1A1HTTAKR1C3TSHRKMT2A
SCHEMBL2851017 0.78 BRAF (0.52) ALDH1A1GFERAKR1C3SMN1; SMN2KMT2A
SCHEMBL7897227 0.76 GFER (0.51) ALDH1A1GFERMAPTHPGDHTT
Sulfuric Acid SCHEMBL9489797 0.76 GFER (0.51) ALDH1A1GFERMAPTHPGDHTT
SCHEMBL2859691 0.75 CYP2C19 (0.55) ALDH1A1HTTAKR1C3TSHRKMT2A
SCHEMBL2850555 0.75 LMNA (0.53) ALDH1A1HTTGAAAKR1C3SMN1; SMN2
SCHEMBL17713153 0.74 CYP2C19 (0.53) ALDH1A1HTTAKR1C3TSHRKMT2A
SCHEMBL5034887 0.74 CYP2C19 (0.76) ALDH1A1HTTGAAAKR1C3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 — — EP claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 — — EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 — — US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 — — US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 ALDH1A1 3589/4885GFER 1096/4885MAPT 3590/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 ALDH1A1 3589/4885GFER 1096/4885MAPT 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback